ストックスクリーナーアプリを入手
15.52
1.37%
0.21
アフターアワーズ：
15.21
-0.31
-2.00%
前日終値:
$15.31
開ける：
$15.41
24時間の取引高:
3.46M
Relative Volume:
1.09
時価総額：
$49.38B
収益：
$29.96B
当期純損益:
$957.25M
株価収益率:
51.05
EPS:
0.304
ネットキャッシュフロー:
$4.77B
1週間 パフォーマンス:
+3.47%
1か月 パフォーマンス:
+6.67%
6か月 パフォーマンス:
+10.38%
1年 パフォーマンス:
+4.30%
1日の値動き範囲:
$15.37
$15.53
1週間の範囲:
$15.08
$15.55
52週間の値動き範囲:
$12.80
$15.55
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
TAK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
The 30-day ADR trend, in yen terms, shows high values for Keyence, Kyocera Corporation Sponsored ADR, and Murata Manufacturing. - 富途牛牛
Takeda Pharma ADR earnings beat by $150.82, revenue fell short of estimates - Investing.com UK
On the 21st, ADR movements in yen terms showed high values for NISSAN MOTOR CO LTD, NINTENDO CO LTD, and Sumitomo Trust. - 富途牛牛
Why This Biotech's Dive Benefits Its Top Three Rivals - Investor's Business Daily
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector (TAK) - Seeking Alpha
Behind Takeda Pharmaceutical Co ADR’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug - Investing.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug By Investing.com - Investing.com South Africa
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Purchased by Allspring Global Investments Holdings LLC - Defense World
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
Nomura Holdings Inc ADR (NYSE:NMR) Shares Acquired by GAMMA Investing LLC - Defense World
Hengan International Group (OTCMKTS:HEGIY) Stock Price Up 3.7% – Time to Buy? - Defense World
Expedia Group Earns RS Rating Upgrade - inkl
GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information - Placera.se
Stocks With Rising Relative Price Strength: IREN - inkl
Stocks With Rising Relative Strength: Dr. Reddy's Labs ADR - inkl
Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com
MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com
On the 10th, the ADR trends show that Takeda Pharmaceutical, Nidec Corporation Sponsored ADR, Advantest, and others are performing well in terms of yen conversion. - 富途牛牛
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
EU approves Takeda’s new Hodgkin lymphoma treatment - Investing.com
IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com
CTVA’s Stock Market Adventure: 22.38% YTD Growth Amidst Volatility - investchronicle.com
Takeda files executive compensation report with SEC - Investing.com
Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl
TD Cowen maintains Buy on Takeda, reiterates $16 target - Investing.com
Stocks With Rising Relative Strength: Novartis ADR - inkl
Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus - Wiley Online Library
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Takeda continues stock plan for management in 2025 - Investing.com
Novavax revises Takeda deal for Japan vaccine sales - Investing.com
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - Yahoo Finance
A significant driver of top-line growth: Takeda Pharmaceutical Co ADR (TAK) - Sete News
Nothing is Better Than C.H. Robinson Worldwide, Inc (CHRW) stock at the moment - Sete News
Takeda Pharmaceutical Co ADR Inc. (TAK) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Carmax Inc: Analyzing KMX Stock Trends - investchronicle.com
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
0.10%
1.81%
大文字化:
|
ボリューム (24 時間):